Journal of Neural Transmission

, Volume 117, Issue 10, pp 1183–1188 | Cite as

Thought disorders among non-demented outpatients with Parkinson’s disease: prevalence and associated factors

  • Rachel Debs
  • Valérie Cochen De Cock
  • Laurence Nègre-Pagès
  • Marina Aristin
  • Anna Senard
  • Olivier Rascol
Movement Disorders - Original Article


The objectives of the study are to evaluate the prevalence and the associated factors of thought disorders in a large cross-sectional population of non-demented out patients with Parkinson’s disease (PD). Four-hundred and nineteen consecutive non-demented PD patients were studied through the DoPaMiP cross-sectional study. Demographic and clinical variables were recorded, including motor and cognitive status, dependency, depressive and anxious symptoms, dysautonomia and sleep disorders. The presence of thought disorders over the past 15 days was assessed by the Unified Parkinson’s Disease Rating Scale part I. Patients with and without thought disorders were compared using parametric tests. Logistic regression was applied to significant data. Thought disorders were present in 105 patients (25%) including vivid dreams in 83 (19.8%), benign hallucinations in 17 (4.1%), and hallucinations without insight in 5 (1.2%). No patient had delusion. Patients with thought disorders were more dependent than the others. Thought disorders were associated with longer PD duration, greater UPDRS scores and the presence of motor complications. Conversely, UPDRS tremor sub-score was lower in patients without thought disorders. Thought disorders were also associated with dysautonomia, lower MMSE score, depression and sleep disorders. Logistic regression identified PD duration, lower MMSE score, depressive and dysautonomic signs as independent risk factors. In conclusion, mild thought disorders were present in 25% of non-demented outpatients with PD, but hallucinations were present in 5% only. Thought disorders were associated with PD duration, depressive and dysautonomic symptoms and lower MMSE score.


Parkinson’s disease Thought disorders Hallucinations Dysautonomia Depression Sleep disorders 


  1. Aarsland D, Larsen JP, Cummins JL et al (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601CrossRefPubMedGoogle Scholar
  2. Adler CH, Sethi KD, Hauser RA et al (1997) Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393–399PubMedGoogle Scholar
  3. Arnulf I, Bonnet AM, Damier P et al (2000) Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 55:281–288PubMedGoogle Scholar
  4. Barnes J, David AS (2001) Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70:727–733CrossRefPubMedGoogle Scholar
  5. Buysse DJ, Reynolds CF 3rd, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213CrossRefPubMedGoogle Scholar
  6. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714CrossRefPubMedGoogle Scholar
  7. Fenelon G, Mahieux F, Huon R et al (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745CrossRefPubMedGoogle Scholar
  8. Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster AI et al (2008) Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 23:484–500CrossRefPubMedGoogle Scholar
  9. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229PubMedGoogle Scholar
  10. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671PubMedGoogle Scholar
  11. Goetz CG, Wuu J, Curgian LM, Leurgans S (2005) Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 64:81–86PubMedGoogle Scholar
  12. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatr 70:734–738CrossRefPubMedGoogle Scholar
  13. Hosmer DW, Lemshow S (1989) Applied logistic regression. Wiley, TorontoGoogle Scholar
  14. International Association for the Study of Pain, Subcommittee on Taxonomy (1986) Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain Suppl 3:S1–S226Google Scholar
  15. Jenkinson C, Fitzpatrick R, Peto V et al (1997) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357CrossRefPubMedGoogle Scholar
  16. Kempster PA, Williams DR, Selikhova M et al (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128CrossRefPubMedGoogle Scholar
  17. Marinus J, Leentjens AF, Visser M et al (2002) Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clin Neuropharmacol 25:318–324CrossRefPubMedGoogle Scholar
  18. Negre-Pages L, Regragui W, Bouhassira D et al (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361–1369CrossRefPubMedGoogle Scholar
  19. Nomura T, Inoue Y, Mitani H et al (2003) Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov Disord 18:812–817CrossRefPubMedGoogle Scholar
  20. Oka H, Yoshioka M, Onouchi K et al (2007) Impaired cardiovascular autonomic function in Parkinson’s disease with visual hallucinations. Mov Disord 22:1510–1514CrossRefPubMedGoogle Scholar
  21. Pacchetti C, Manni R, Zangaglia R et al (2005) Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord 20:1439–1448CrossRefPubMedGoogle Scholar
  22. Pappert EJ, Goetz CG, Niederman FG et al (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord 14:117–121CrossRefPubMedGoogle Scholar
  23. Postuma RB, Gagnon JF, Montplaisir J (2008) Autonomic dysfunction in RBD—what can it teach us about disease progression? Sleep Med 9:473–474CrossRefPubMedGoogle Scholar
  24. Rascol O, Dubois B, Caldas AC et al (2006) Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Disord 21:2110–2115CrossRefPubMedGoogle Scholar
  25. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson disease. Arch Neurol 53:1265–1268PubMedGoogle Scholar
  26. Schwab R, England A (1969) Projection techniques for evaluating surgery in Parkinson’s disease. In: Edinburgh RCoSi (ed) Third symposium on Parkinson’s disease. E. & S. Livingstone Ltd, pp 152–157Google Scholar
  27. Schwab RS, England AC Jr, Poskanzer DC et al (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208:1168–1170CrossRefPubMedGoogle Scholar
  28. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132:2947–2957CrossRefPubMedGoogle Scholar
  29. Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 49:724–728PubMedGoogle Scholar
  30. Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG et al (2009) Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73:1469–1477CrossRefPubMedGoogle Scholar
  31. Williams-Gray CH, Foltynie T, Brayne CE et al (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 13:1787–1798CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Rachel Debs
    • 1
  • Valérie Cochen De Cock
    • 1
    • 5
  • Laurence Nègre-Pagès
    • 2
    • 3
  • Marina Aristin
    • 3
  • Anna Senard
    • 1
  • Olivier Rascol
    • 1
    • 2
    • 4
  1. 1.Department of NeurosciencesUniversity HospitalToulouseFrance
  2. 2.Department of Clinical PharmacologyUniversity HospitalToulouseFrance
  3. 3.LN-Pharma, Neurosciences Et Neuro-Epidemiology Research UnitToulouseFrance
  4. 4.INSERM U-825/CIC, University HospitalToulouseFrance
  5. 5.Centre Atrophie Multi SystématiséeToulouse Cedex 9France

Personalised recommendations